Prostatic artery embolization (PAE) using polyethylene glycol microspheres: safety and efficacy in 81 patients
Prostatic hyperplasia
Lower urinary tract symptoms
Prostatic artery embolization
Issue Date: 
This article is licensed under a Creative Commons Attribution 4.0 International License,
Insausti, I.; Galbete, A.; Lucas-Cava, V.; et al. "Prostatic artery embolization (PAE) using polyethylene glycol microspheres: safety and efficacy in 81 patients". CardioVascular and Interventional Radiology. 45 (9), 2022, 1339 - 1348
Purpose To evaluate the safety and efficacy of prostatic artery embolization (PAE) using polyethylene glycol microspheres (PEGM) in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Materials and methods This multicentric prospective study enrolled 81 patients who underwent PAE with 400 +/- 75 mu m PEGM (HydroPearl (R), Terumo, Japan). Results from baseline and 1-, 3-, 6-, and 12-month follow-ups were assessed for subjective outcomes including International Prostate Symptoms Score (IPSS), Quality of life (QoL), and International Index of Erectile Function, and objective outcomes such as peak urinary flow (Qmax) and post-void residual volume (PVR). The visual analogue scale, satisfaction questionnaire, prostatic volume, and prostatic specific antigen levels were also evaluated. Complications were documented using the modified Clavien-Dindo classification. Results Technical success was obtained in all patients. Clinical success was achieved in 78.5% of patients. Before PAE, 54.3% of patients had an indwelling catheter which was removed in 75% of them after procedure. A statistically significant decrease was observed in IPSS and QoL from baseline to 12 months (20.14 vs 5.89; 4.8 vs 0.63, P < .01), respectively. Objective outcomes also showed a statistically significant improvement in Qmax (+ 114.9%; P < .01), achieving a maximum urinary flow of 14.2 mL/sec, and PVR (decrease 58%; P < .05) at 12 months. Minor complications (Clavien-Dindo grades I-II) occurred in 13.6% of patients, without major complications observed. Conclusion PAE with PEGM is safe and effective treatment in patients with symptomatic BPH, with a significant improvement in both subjective and objective outcomes.

Files in This Item:
379.86 kB
Adobe PDF

Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.